P atient unmet needs from neurologic disorders are staggering, and the cost to society is enormous. As most OECD countries see a “greying” of their populations, the burdens of many of these later-onset neurologic conditions will skyrocket. All of this creates an imperative to act – and to invest in new therapies. Neuroscience venture funding in the past five years is 40% higher than it was in the prior five years, with most of that increase coming in the last few years.
- Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th
- Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants with Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021
- Cortexyme to Present Additional Top-line GAIN Trial Results and Analysis at CTAD 2021 on November 11th
- Cortexyme Reports GAIN Trial Data Demonstrated Relationship Between Reduction of P. gingivalis Infection and Slowing of Alzheimer’s Disease Progression
- Cortexyme to Present Results from the GAIN Trial: A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease at CTAD 2021